We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model.
- Authors
Zhiqin Wu; Qingwei Chen; Dazhi Ke; Guiqiong Li; Wei Deng
- Abstract
Diabetes mellitus (DM) has been recognized as a major health problem. Emodin (Emo) has been reported to exhibit protective effects against diabetic nephropathy. However, little has been known about the effect of Emo on diabetic cardiomyopathy (DCM). A type 2 DM model was induced in rats by low dose streptozotocin (STZ) combined with high energy intake. We found that Emo-treated groups displayed significantly higher body weight (BW) and lower heart weight (HW)/BW. Furthermore, Emo could significantly decrease blood glucose, total cholesterol (TG) levels, and triglyceride (TC) levels in diabetic rats. Moreover, the Emo-treated group showed a marked increase in heart rate (HR) and showed lower left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular posterior wall thickness (LWPWT), and interventricular septal diastolic wall thickness (IVSD). Emo induced a significant increase in phosphorylation of Akt and GSK-3β in myocardium. These results suggest that Emo may have great therapeutic potential in the treatment of DCM by Akt/GSK-3β signaling pathway.
- Subjects
EMODIN; CARDIOMYOPATHIES; DIABETES; LABORATORY rats; DIABETIC nephropathies; STREPTOZOTOCIN; BODY weight
- Publication
Molecules, 2014, Vol 19, Issue 9, p14782
- ISSN
1420-3049
- Publication type
Article
- DOI
10.3390/molecules190914782